Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Myasthenia Gravis 4Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Lymphocytic, Chronic, B-Cell 2Common Variable Immunodeficiency 1Agammaglobulinemia 1

Interventions

Rituximab 344Cyclophosphamide 317fludarabine phosphate 142Etoposide 139Peripheral Blood Stem Cell Transplantation 124fludarabine 112Filgrastim 112Mycophenolic Acid 98Melphalan 98Whole-Body Irradiation 90Vincristine 90Busulfan 87Cytarabine 85Doxorubicin 79Cyclosporine 76Tacrolimus 75Radiotherapy 75Prednisone 73Bendamustine Hydrochloride 72Granulocyte Colony-Stimulating Factor 66Methotrexate 65Antilymphocyte Serum 56Carmustine 54Dexamethasone 50Gemcitabine 48Lenalidomide 46Bortezomib 43venetoclax 41ibritumomab tiuxetan 37obinutuzumab 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × Hizentra × Clear all
NCT07582432 2026-05-12

SIGMA

Grifols Biologicals, LLC

Phase 3 Recruiting
49 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03211065 2021-04-19

Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig

Rochester General Hospital

Phase 2/3 Completed
16 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡